Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Part the Cloud Translational (PTC) Research for Alzheimer’s Disease Program: Phase 1 and Phase 2 Clinical Studies

    Part the Cloud Translational Research supports academic investigators and small companies in testing treatments and disease-progression biomarkers to advance Alzheimer’s and related dementia research.

    OverviewSimilar Grants
    OverviewSimilar Grants

    This grant was recently updated

    Full application deadlines moved from December 15, 2026 to January 5, 2027, and for ISTAART members from December 17, 2026 to January 7, 2027 (5 p.m. ET). Repurposed-drug study guidance also replaces “pre-symptomatic” with a repeated “symptomatic.”

    Part the Cloud Translational Research for Alzheimer’s Disease Program: Combination Therapies Program (PTC-CTP)

    Part the Cloud Combination Therapies Program supports researchers conducting Phase 1–3 trials of combined therapies for Alzheimer’s and related dementias to inform further treatment development.

    Alzheimers AssociationDue Jan 5, 2027$3,000,000

    Part the Cloud Translational Research for Alzheimer’s Disease Program: Enable the Molecule for Artificial Intelligence-Discovered Programs (PTC-EM-AI) Funding Program

    PTC-EM-AI supports researchers advancing AI-discovered therapies for Alzheimer's and related dementias through lead optimization and IND-enabling studies to prepare candidates for clinical development.

    Alzheimers AssociationDue Jan 5, 2027$1,000,000

    Tau Pipeline Enabling Program V (T-PEP)

    Tau Pipeline Enabling Program V (T-PEP) supports researchers developing therapeutic candidates targeting tau or related mechanisms to advance potential disease-modifying treatments for tauopathies.

    Alzheimers AssociationForecasted May 28, 2027$750,000Forecasted

    Drug Development RFP

    Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.

    Alzheimers Drug DiscoveryDue Dec 7, 2026· 17d$5,000,000

    Prevention RFP - Alzheimer's Drug Discovery Foundation

    Prevention RFP - Alzheimer's Drug Discovery Foundation supports researchers and clinicians conducting human studies of targeted interventions, combination therapies, and drug choices to reduce dementia risk.

    Alzheimers Drug DiscoveryForecasted Dec 7, 2026· 17d$5,000,000Forecasted